tirzepatide in adolescents A Study of With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) Tirzepatide as a Potential Disease-Modifying

Description

primary endpoint) ( The efficacy and safety of tirzepatide, with a special focus on cardiovascular safety, were investigated in the 52-week SURPASS-4 trial testing tirzepatide versus insulin glargine in adults with T2D and a high cardiovascular risk under inadequate glycemic control at baseline on one to three oral glucose-lowering medications (metformin, sulfonylurea, SGLT-2 inhibitor) ( vs

Love following these updates.

My doctor says I can stay on it for as long as Im comfortable

Note: Do not change, skip, split, or restart insulin without medical guidance

Kraus D, Yang Q, Kong D, Banks AS, Zhang L, Rodgers JT, Pirinen E, Pulinilkunnil TC, Gong F, Wang YC, Cen Y, Sauve AA, Asara JM, Peroni OD, Monia BP, Bhanot S, Alhonen L, Puigserver P, Kahn BB